Samsung Audit & Supervisory Board: "Semiconductor Investments in Honam and Chungcheong Regions Must Not Be Driven by Political Considerations"
First Public Statement Amid Growing Calls for Semiconductor Investment Outside the Capital Region
"Corporate Sustainability and Impact on the National Economy Must Be Prioritized"
On Labor-Management Negotiations: "We’ve Cleared the First Hurdle… More Communication Is Needed"
Regarding the Controversy Over the Legality of Performance Bonuses: "No Specific Issues Found"
[Edaily Reporter Song Jae-min] Lee Chan-hee, Chairman of Samsung’s Compliance Oversight Committee, stated regarding the recent proposals for semiconductor investments in the Honam and Chungcheong regions, “We will monitor the situation closely to ensure we are not swayed by political logic.”
Lee Chan-hee, Chairman of Samsung’s Compliance Oversight Committee, attends a regular meeting of the committee held at the Samsung Life Insurance Seocho Building in Seocho-gu, Seoul, on the 16th. (Photo by Reporter Song Jae-min) Chairman Lee made these remarks to reporters prior to the Compliance Oversight Committee’s regular meeting held on the 16th at the Samsung Life Insurance Seocho Building in Seocho-gu, Seoul, in response to a question about the possibility of Samsung Electronics investing in semiconductor facilities outside the Seoul metropolitan area.
He said, "If this leads to actual investment, we expect it to become a matter for discussion by the Compliance Oversight Committee, just as with the issues we have handled so far."
He added, “In that process, the Compliance Oversight Committee will closely monitor the situation to ensure that the decision is not swayed by political logic without considering the company’s sustainability and the impact on the national economy.”
In line with the government’s recent policy on balanced national development, calls for Samsung Electronics and SK Hynix to invest in semiconductor facilities in the Honam and Chungcheong regions have been raised repeatedly, primarily by political circles and local governments. Amid ongoing discussions about expanding semiconductor production hubs and AI infrastructure to non-metropolitan areas, Chairman Lee’s public statement on the matter is interpreted as making it clear that economic viability and industrial competitiveness must be prioritized in future investment discussions.
Chairman Lee also addressed labor-management relations at Samsung Electronics. Regarding the recent conclusion of wage and collective bargaining negotiations, he remarked, “To climb a high mountain, one must pass through many peaks,” adding, “This time, we have crossed the first peak, and much experience and mutual communication will be needed before labor-management relations are fully established.”
He added, “Starting next year, given the public’s interest following this year’s Samsung labor-management negotiations, I believe we should proceed with greater attention to those aspects.”
Regarding the recently controversial “n% of operating profit” performance bonus payment method, he stated, “I believe this was implemented after sufficient legal review within Samsung,” and added, “The Compliance Oversight Committee has not yet identified any specific issues regarding that matter.”
Regarding the allegations of front-running involving Rainbow Robotics, he said, “The Compliance Oversight Committee has not yet looked into this matter,” adding, “If it becomes an issue in the future and falls under the jurisdiction of the Compliance Oversight Committee, we will investigate it thoroughly.”
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…